Celebrating the success of the COVID-19 vaccines, and looking to the future

It’s been over three years since I saw my first COVID-19 patient in the emergency department. The image of that x-ray is burned into my memory: clusters of white spots spread out across both sides of...
Read More
IRA Impacts: Cancer treatment research and development

Last month marked the one-year anniversary of the reignited Cancer Moonshot, the White House’s ambitious goal of reducing the death rate from cancer by at least 50% over the next 25 years. Much of...
Read More
Food Allergy Highlights Opportunities for Inclusive, Representative Research Studies

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The PhRMA blog welcomes guest...
Read More
PhRMA submits comments to OSTP on enhancing clinical trial diversity

The White House’s Office of Science and Technology Policy (OSTP) recently solicited stakeholder feedback on the clinical research infrastructure for emergency clinical trials, for which PhRMA...
Read More
U.S. biopharmaceutical exports support jobs, innovation

The U.S. Census Bureau and the U.S. Bureau of Economic Analysis recently published annual trade data indicating that U.S. exports of goods exceeded $2 trillion in 2022. According to the report, U.S....
Read More
What we’ve learned from three years of fighting COVID-19

Three years ago, amidst an unprecedented public health crisis, biopharmaceutical industry made a commitment to fight COVID-19. Leveraging decades of research and investments in emerging technologies...
Read More
Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?

In December 2022, the United States launched negotiations for the Indo-Pacific Economic Framework (IPEF) with thirteen countries throughout the Indo-Pacific region, including Australia, India,...
Read More
Insurer and PBM tactics are shifting higher costs to patients with chronic and complex conditions

Health plans are increasingly using deductibles and coinsurance to shift more of the cost of care to chronically ill patients taking brand medicines. As data from IQVIA show, this alarming trend is...
Read More
Why Congress should prioritize fixing the 340B program

Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to...
Read More
FDA-USPTO collaboration initiatives should be evidence-based, prioritize innovation

The United States Patent and Trademark Office (USPTO) and the U.S. Food and Drug Administration (FDA) are in the process of considering new collaboration initiatives aimed at biopharmaceutical...
Read More